News about Global Pharma

Interna Therapeutics and Daiichi Sankyo Partner to Advance MNM-Based Targeted Delivery Technology

Interna Therapeutics and Daiichi Sankyo collaborate to advance MNM-based targeted delivery technologies, aiming to enhance intracellular delivery, boost therapeutic activity, and improve performance across key drug development programs.

Global Pharma | 17/04/2026 | By News Bureau |  100

Mabwell Strengthens China Pipeline with NMPA Acceptance for Denosumab

Mabwell announces NMPA acceptance of its sBLA for MAIWEIJIAN (denosumab), China’s first approved 120mg denosumab biosimilar, used to treat giant cell tumor of bone in adults and adolescents.

Global Pharma | 17/04/2026 | By News Bureau

Kazia Expands Oncology Platform with First-in-Class SETDB1 Inhibitor

Kazia Therapeutics expands its oncology platform with a first-in-class SETDB1 inhibitor, leveraging an AI-driven epigenetic drug discovery engine for faster and scalable candidate development.

Global Pharma | 15/04/2026 | By News Bureau |  122

Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer

Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.

Global Pharma | 13/04/2026 | By News Bureau |  120

Daiichi Sankyo Partners with Imagene AI for Biomarker Discovery

Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.

Global Pharma | 11/04/2026 | By News Bureau |  122

Inventia Healthcare Launches Generic Dapagliflozin in US After FDA Approval

Inventia Healthcare has secured FDA approval for dapagliflozin tablets and begun Day-One commercialisation, expanding access to affordable diabetes and heart failure treatment in the US.

Global Pharma | 09/04/2026 | By News Bureau |  133

Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer

The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.

Global Pharma | 08/04/2026 | By News Bureau

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Global Pharma | 08/04/2026 | By News Bureau

Neurocrine Biosciences to Acquire Soleno Therapeutics in USD 2.9 Billion Deal

The acquisition brings first-in-class Prader-Willi syndrome therapy VYKAT XR into Neurocrine’s portfolio, strengthening its position in endocrinology and rare diseases.

Global Pharma | 07/04/2026 | By News Bureau

University of Manchester Develops SAFER-Dem Tool to Improve Dementia Patient Discharges

Researchers develop SAFER-Dem, a new care tool designed to make hospital discharge safer and more patient-centred for people living with dementia.

Global Pharma | 06/04/2026 | By News Bureau